LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Arcus Biosciences Inc

Închisă

SectorSănătate

9.24 -1.18

Rezumat

Modificarea prețului

24h

Curent

Minim

9.09

Maxim

9.31

Indicatori cheie

By Trading Economics

Venit

-18M

-112M

Vânzări

2M

28M

EPS

-1.14

Marjă de profit

-400

Angajați

627

EBITDA

-34M

-122M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+173.7% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

90M

1.1B

Deschiderea anterioară

10.42

Închiderea anterioară

9.24

Sentimentul știrilor

By Acuity

50%

50%

177 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Arcus Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 iun. 2025, 22:33 UTC

Achiziții, Fuziuni, Preluări

Millicom to Acquire Telefonica Ecuador for $380 Million

13 iun. 2025, 23:50 UTC

Achiziții, Fuziuni, Preluări

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 iun. 2025, 23:20 UTC

Achiziții, Fuziuni, Preluări

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 iun. 2025, 23:09 UTC

Achiziții, Fuziuni, Preluări

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 iun. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 iun. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Millicom to Acquire Telefonica Ecuador for $380M

13 iun. 2025, 22:04 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 iun. 2025, 21:42 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 iun. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

Bunge: Outside Date Extended to July 3

13 iun. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 iun. 2025, 21:34 UTC

Achiziții, Fuziuni, Preluări

Bunge Gets Mexico Approval for Viterra Deal

13 iun. 2025, 21:32 UTC

Achiziții, Fuziuni, Preluări

Bunge Gets China Approval for Viterra Deal

13 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 iun. 2025, 20:45 UTC

Achiziții, Fuziuni, Preluări

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 iun. 2025, 20:34 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 iun. 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 iun. 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 iun. 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 iun. 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13 iun. 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13 iun. 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 iun. 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Comparație

Modificare preț

Arcus Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

173.7% sus

Prognoză pe 12 luni

Medie 25.29 USD  173.7%

Maxim 46 USD

Minim 12 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcus Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

8

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

8.01 / 8.75Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Neutral Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

177 / 380 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.